US 11,998,550 B2
Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation
Joel Rosenbloom, Wynnewood, PA (US); and Edward John Macarak, Chadds Ford, PA (US)
Assigned to THOMAS JEFFERSON UNIVERSITY, Philadelphia, PA (US)
Appl. No. 16/607,032
Filed by Thomas Jefferson University, Philadephia, PA (US)
PCT Filed Apr. 20, 2018, PCT No. PCT/US2018/028516
§ 371(c)(1), (2) Date Oct. 21, 2019,
PCT Pub. No. WO2018/195392, PCT Pub. Date Oct. 25, 2018.
Claims priority of provisional application 62/487,802, filed on Apr. 20, 2017.
Prior Publication US 2020/0046708 A1, Feb. 13, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/12 (2006.01); A61P 11/00 (2006.01); A61P 41/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/12 (2013.01); A61P 11/00 (2018.01); A61P 41/00 (2018.01)] 3 Claims
OG exemplary drawing
 
1. A method of reducing the occurrence of excessive fibrin formation in a patient consisting of administering to said patient one effective dose of Trametinib (GSK1120212) sufficient to reduce the fibrin formation prior to a surgical procedure, and a further dose of the Trametinib (GSK1120212) for seven days after said surgical procedure daily, wherein the effective dose of Trametinib (GSK1120212) is between 0.01 mg to 1.5 mg.